Insulin, a therapeutic peptide for Type I diabetes, can interact with polymers commonly found in healthcare settings via hydrophobic interactions, potentially triggering agglomeration while reducing its bioavailability and therapeutic efficacy.
Fagihi et al. (Thu,) studied this question.